Phase 2 Stomach Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with stomach (gastric) cancer of a specific type called adenocarcinoma, where lab tests show the tumour is HER2-negative, and who have not had surgery to remove the primary tumour or any spread of the cancer
• People whose stomach cancer has spread to the lining of the abdomen (peritoneal metastases), confirmed or requiring confirmation by a keyhole surgical procedure called laparoscopy, and who do not have a blockage in the stomach outlet or intestines
• People whose tumour tests positive for a protein called Claudin 18.2 at specific levels (confirm with trial site for exact thresholds)
• People aged 18 or older at the time of registration
• People who are generally able to carry out daily activities with little or no difficulty, based on a standard performance scale (ECOG score of 0 or 1)
• People who are expected to live for more than 3 months
• People whose bone marrow, liver, and kidneys are functioning well enough, as shown by blood tests

Who may not be able to join:

• People whose cancer has spread to places other than the abdominal lining, such as the liver, lungs, or nearby lymph nodes
• People who are pregnant, have given birth within the last 28 days, or are currently breastfeeding
• People who have previously received certain immune therapies (such as PD-1, PD-L1, or CTLA-4 treatments) or targeted therapy directed at the Claudin 18.2 protein
• People who have had another cancer diagnosis either at the same time or within the past 5 years
• People with severe mental illness, uncontrolled epilepsy, or significant disease of the brain or nervous system
• People with serious active heart problems, such as significant heart failure, troublesome irregular heartbeat requiring medication, or a heart attack within the past 12 months
• People with a blockage or significant problem in the upper digestive tract that could prevent a study medication called S-1 from being properly absorbed
• People with known nerve damage in the hands or feet beyond a mild level (confirm with trial site)
• People who are taking steroids or immune-suppressing medications following an organ transplant
• People with severe infections that cannot be controlled, or other severe uncontrolled health conditions
• People with moderate or severe kidney problems, based on specific kidney function test results (confirm with trial site for exact thresholds)
• People known to be missing an enzyme called DPD, which is needed to process certain chemotherapy drugs safely
• People who have had a severe allergic reaction to paclitaxel (a chemotherapy drug) or to any ingredient in the study medications
• People with an active autoimmune disease (where the immune system attacks the body) or a history of a hard-to-treat autoimmune condition
• People who are HIV-positive, or who have active hepatitis B or hepatitis C infections at specific levels requiring antiviral treatment (confirm with trial site for exact definitions)
• People who have used steroids or other immune-suppressing medicines in the 14 days before joining the trial, with some exceptions for low-dose or locally applied treatments (confirm with trial site)
• People with uncontrolled irregular heartbeat, a heart attack in the 12 months before joining, or active tuberculosis

Important: Always verify eligibility with the trial site directly before applying.